INSY News Alert Insys Therapeutics Inc (INSY) 41.52 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Insys Therapeutics Inc (INSY) 41.52 $INSY

Stocks Hold Near Session Highs; FedEx Bounces Back
at Investor's Business Daily - Thu Dec 18, 1:52PM CST
Stocks held steady and near session highs heading into the final hour of trading Thursday. The Nasdaq led in the stock market today, climbing 1.7%. The S&P 500 and Dow Jones industrial average each picked up 1.6%. Volume on the NYSE and Nasdaq was...
FDX: 176.42 (-0.52), BIIB: 340.89 (+5.13), INSY: 41.52 (+0.51), CTAS: 79.86 (+0.22)

Will INSYS (INSY) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 8:28AM CST
Will INSYS (INSY) Continue to Surge Higher?
INSY: 41.52 (+0.51)

RedHill submits MAA for ondansetron
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:38AM CST

INSY: 41.52 (+0.51), TSRO: 36.80 (+0.57), HRTX: 9.75 (+0.02), RDHL: 12.22 (-0.13), GWPH: 68.08 (+1.82), OPK: 9.63 (+0.21), GALE: 1.49 (-0.02)

Insys Therapeutics Receives FDA Orphan Drug Designation for Liposome Entrapped Paclitaxel as a Potential Treatment for Gastric Cancer
Marketwired - Tue Dec 09, 6:00AM CST
Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its Liposome Entrapped Paclitaxel Easy to Use ("LEP-ETU" candidate for the treatment of gastric cancer. LEP-ETU is an improved formulation of paclitaxel, a widely used chemotherapeutic agent.
INSY: 41.52 (+0.51)

Why GW Pharmaceuticals Is Currently The Only Game In Town For A Cannabis Play
Nick Cox - at Seeking Alpha - Mon Dec 08, 10:59AM CST

INSY: 41.52 (+0.51), GWPH: 68.08 (+1.82)

Novus Becomes an Insurance Leader as MMJ Market Approaches Tipping Point
ACCESSWIRE - Mon Dec 08, 9:21AM CST
WHITEFISH, MT / ACCESSWIRE / December 8, 2014 / A unique company in the MMJ space today that is focused on the medical insurance side of the business is Novus Acquisition & Development (OTC: NDEV). Novus provides health insurance and insurance related solutions to the growing wellness and MMJ markets using an innovative cost-saving provider network model that is administered via their wholly-owned Novus Medical Group subsidiary's Novus MedPlan. The timely rollout of the Novus MedPlan in states where MMJ is legal, which gives patients access to considerable discounts on MMJ products for a modest subscriber fee of under $20 a month, was recently highlighted in Forbes as the number one pick, taking the top slot out of a list of the eight hottest publicly traded companies to draw the interest of investors in this rapidly emerging sector.
CARA: 9.78 (+0.02), INSY: 41.52 (+0.51), GWPH: 68.08 (+1.82)

Meridian Bioscience: A Strong Sell on Dismal Q4, Competition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 12:40PM CST
On Dec 2, 2014, Zacks Investment Research downgraded diagnostic test-kit maker Meridian Bioscience Inc. (VIVO) to a Zacks Rank #5 (Strong Sell).
ICUI: 83.38 (+1.63), INSY: 41.52 (+0.51), VIVO: 16.68 (-0.02), OSUR: 10.26 (+0.25)

Parallel Comparison Analyses Confirm That Insys Therapeutics' Synthetic CBD Is Identical in Chemical Structure to Plant-Derived CBD
Marketwired - Thu Dec 04, 6:02AM CST
Independent comparison analyses have found that cannabidiol (CBD) synthetically produced by Insys Therapeutics, Inc. (NASDAQ: INSY) is chemically identical to plant-derived CBD. Analyses were conducted independently by Insys and the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.
INSY: 41.52 (+0.51)

Insys' promotion of narcotic continues to draw attention
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 12:38PM CST

INSY: 41.52 (+0.51)

Insys' Cannabidiol Gets another Orphan Drug Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 9:40AM CST
Insys Therapeutics, Inc.'s (INSY) pharmaceutical cannabidiol (CBD) candidate received orphan drug designation from the FDA for the treatment of pediatric schizophrenia.
IPXL: 31.32 (+0.26), AGN: 210.12 (+0.95), LCI: 42.29 (+1.79), INSY: 41.52 (+0.51)

Insys cannabidiol tagged an Orphan Drug for pediatric schizophrenia
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 12:10PM CST

INSY: 41.52 (+0.51)

3 Fast-Growing Biotech Stocks To Buy in December
Todd Campbell, The Motley Fool - Motley Fool - Mon Nov 24, 9:46AM CST
Year end is coming up quickly, and that has investors pouring over portfolios, dissecting financial reports, and considering names to own heading into 2015.  With that in mind, read on to learn why  I think these three biotech stocks may prove...
INSY: 41.52 (+0.51), EBS: 27.64 (+1.28), CBST: 100.29 (-0.09)

Cardica (CRDC) in Focus: Stock Moves Up 8.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 7:37AM CST
Cardica Inc. (CRDC) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
ICUI: 83.38 (+1.63), INSY: 41.52 (+0.51), GWPH: 68.08 (+1.82), CRDC: 0.69 (unch)

Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Pediatric Schizophrenia
Marketwired - Mon Nov 24, 6:01AM CST
Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its pharmaceutical cannabidiol (CBD) candidate for the treatment of pediatric schizophrenia. This marks the fifth ODD for the company's CBD program.
INSY: 41.52 (+0.51)

The Real Reason Marijuana is a Dangerous Investment
Sean Williams, The Motley Fool - Motley Fool - Sun Nov 23, 11:18AM CST
Source: Flickr user Isabel Mancera. When it comes to hot investing opportunities , few are likely to raise the eyebrows of traders these days more than marijuana. Estimates as to how big the legal marijuana market could eventually become vary...
INSY: 41.52 (+0.51), GWPH: 68.08 (+1.82)

Could Warren Buffett's Investing Strategy Include Marijuana Stocks?
Sean Williams, The Motley Fool - Motley Fool - Sat Nov 22, 11:39AM CST
Few investors  are as highly regarded -- and as successful -- as the Oracle of Omaha, Warren Buffett. In just over six decades, Buffett's investing strategy has grown his wealth from about $10,000  to more than $71 billion. Not too shabby, right? ...
INSY: 41.52 (+0.51), GWPH: 68.08 (+1.82)

Insider Trading Alert - INSY, LNKD And IMPV Traded By Insiders
at The Street - Fri Nov 21, 9:30AM CST
Stocks with insider trader activity include INSY, LNKD and IMPV
INSY: 41.52 (+0.51), LNKD: 231.83 (+0.34), IMPV: 51.87 (+1.18)

3 Healthcare Stocks Short-Sellers Are Wrong About
Motley Fool Staff - Motley Fool - Fri Nov 21, 9:27AM CST
Short-sellers have been piling into a number of healthcare stocks lately. This trend lends itself well to the possibility of exploiting a so-called "short squeeze", where share prices rise as short-sellers scramble to cover their positions. We asked...
JNJ: 104.59 (+0.31), INSY: 41.52 (+0.51), GERN: 3.06 (+0.05), RMTI: 8.41 (-0.07)

Insys Therapeutics to Present at 26th Annual Piper Jaffray Healthcare Conference
Marketwired - Wed Nov 19, 4:16PM CST
Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that Michael L. Babich, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, will present at the 26th Annual Piper Jaffray Healthcare Conference as follows:
INSY: 41.52 (+0.51)

Weakness Seen in Vascular Solutions (VASC): Stock Plunges 22.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 7:52AM CST
Vascular Solutions has been witnessing a negative trend in its current year earnings estimate and its share price has showed a sharp decline in the last 24 hours
ICUI: 83.38 (+1.63), INSY: 41.52 (+0.51), GWPH: 68.08 (+1.82), VASC: 27.30 (+0.71)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Lennar's 6.73% Slide Puts Disclosure Claims in Focus

Updated Category News Views 12

A homebuilder can survive ugly margins; murky demand signals are another beast entirely. Lennar is staring at a securities class action after a bruising run of disclosures and market reactions, and the central issue is not whether housing got tougher. Everybody with a pulse knew rates were squeezing buyers. The issue is whether NYSE:LEN gave investors a sufficiently clear...

Continue Reading
AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading
Industrial Air Compressors: Fix, Rebuild, or Replace

Updated Category News Views 90

A compressor’s ugliest invoice is rarely the one from the service technician. It is the one nobody sees at first: a stalled production line, missed output, overtime, wasted electricity, and a maintenance crew chasing the same machine again next month. Pam Mahood of Waterloo, Iowa-based Compressed Air & Equipment Co. puts the decision where it belongs—not on the price...

Continue Reading
Hoymiles Brings Plug-In Solar Flexibility to RE+ 2026

Updated Category News Views 105

A 1.8-kilogram box may not sound like much, but it captures where household solar is trying to go: smaller, less intimidating, and far easier to put to work. At RE+ 2026 in Las Vegas, Hoymiles laid out a residential lineup spanning plug-in solar, battery storage and conventional rooftop microinverters. This was not one flashy gadget looking for applause. It was a fairly...

Continue Reading
Triller Lawsuit Puts Merger Disclosures Under a Harsh Light

Updated Category News Views 90

A $0.32 closing price has a way of stripping the paint off a corporate story. The proposed securities class action involving Triller Group, Inc. puts a hard spotlight on a familiar, ugly market sequence: a splashy merger, glowing talk around acquired assets, delayed financial filings, Nasdaq trouble, and then a collapse severe enough to leave shareholders wondering what...

Continue Reading
Sports Leagues Confront Youth Gambling's Hard Truth

Updated Category News Views 70

A stadium-sized advertising machine cannot pretend kids are not watching. That is the uncomfortable backdrop to the National Council on Problem Gambling's November 10 youth gambling prevention summit, where representatives from the NFL, MLB, NBA and PGA Tour met at the NFL's New York offices. Good that they showed up. Frankly, with gambling stitched into so much sports...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 149

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover Sustainability LIVE: The Middle East Summit 2026 Insights

Updated Category News Views 218

BizClik Announces Sustainability LIVE: The Middle East Summit BizClik, the renowned global B2B media company behind the well-known Sustainability Magazine, is setting the stage for an ambitious event called Sustainability LIVE: The Middle East Summit. This summit is scheduled to take place virtually from 3-4 February 2026, providing a unique opportunity for leaders in...

Continue Reading
Bureau Veritas Ceases Discussions on Business Merger Plans

Updated Category News Views 137

Bureau Veritas Concludes Discussions on Future Collaboration In a recent declaration, Bureau Veritas disclosed that discussions surrounding a potential merger with SGS have ceased. The talks, which commenced with optimism about the potential synergies between the two leading firms in the Testing, Inspection, and Certification (TIC) industry, did not reach a conclusive...

Continue Reading
Bernstein's Insights: Why Royal Caribbean Outshines Carnival

Updated Category News Views 295

Bernstein Analyzes the Cruise Industry Landscape Recently, Bernstein analysts took a deep dive into the cruise industry, comparing two major players: Royal Caribbean (NYSE: RCL) and Carnival (NYSE: CCL). The analysts have awarded an Outperform rating to Royal Caribbean while assigning a Market-Perform rating to Carnival, based on recent assessments of the sector....

Continue Reading
NRG Energy's Impressive Q4 Performance and Exciting Future Plans

Updated Category News Views 498

NRG Energy Reports Strong Fourth Quarter Performance NRG Energy, Inc. (NYSE: NRG) has witnessed an uptick in its stock price following the announcement of its fourth-quarter results for 2024. Despite missing revenue expectations, the company demonstrated remarkable profitability. Revenue and Earnings Overview During the fourth quarter, NRG Energy reported revenues of...

Continue Reading
OpenText Introduces Cutting-Edge AI Platform for Enterprises

Updated Category News Views 317

Transforming Data Management with AI Technology OpenText has unveiled an exciting new platform that revolutionizes how enterprises manage their data. This next-generation AI Data Platform streamlines data management while incorporating innovative AI capabilities that empower organizations to activate their information securely. As the digital landscape continues to...

Continue Reading